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Abstract
Like most complex phenotypes, exceptional longevity is thought to reflect a combined influence of environmental (e.g.,
lifestyle choices, where we live) and genetic factors. To explore the genetic contribution, we undertook a genome-wide
association study of exceptional longevity in 801 centenarians (median age at death 104 years) and 914 genetically matched
healthy controls. Using these data, we built a genetic model that includes 281 single nucleotide polymorphisms (SNPs) and
discriminated between cases and controls of the discovery set with 89% sensitivity and specificity, and with 58% specificity
and 60% sensitivity in an independent cohort of 341 controls and 253 genetically matched nonagenarians and centenarians
(median age 100 years). Consistent with the hypothesis that the genetic contribution is largest with the oldest ages, the
sensitivity of the model increased in the independent cohort with older and older ages (71% to classify subjects with an age
at death.102 and 85% to classify subjects with an age at death.105). For further validation, we applied the model to an
additional, unmatched 60 centenarians (median age 107 years) resulting in 78% sensitivity, and 2863 unmatched controls
with 61% specificity. The 281 SNPs include the SNP rs2075650 in TOMM40/APOE that reached irrefutable genome wide
significance (posterior probability of association=1) and replicated in the independent cohort. Removal of this SNP from
the model reduced the accuracy by only 1%. Further in-silico analysis suggests that 90% of centenarians can be grouped
into clusters characterized by different ‘‘genetic signatures’’ of varying predictive values for exceptional longevity. The
correlation between 3 signatures and 3 different life spans was replicated in the combined replication sets. The different
signatures may help dissect this complex phenotype into sub-phenotypes of exceptional longevity.
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Introduction
The average human lifespan in developed countries now ranges
from about 80 to 85 years. Environmental factors such as lifestyle
choices and where we choose to live as well as genetic factors all
contribute to healthy aging. Supporting the importance of
environmental factors in survival to old age is the 88 year average
life expectancy of Seventh-Day Adventists [1], who by virtue of
their religion have health related behaviors conducive to healthy
aging.
Human twin studies suggest that only 20–30% of the variation
in survival to about 85 years is determined by genetic variation [2].
However, the existence of rare families demonstrating remarkable
clustering for extreme ages [3,4], the increased relative risks of
survival amongst siblings of nonagenarians [5] and of centenarians
[6,7,8,9,10,11,12,13], the fact that children of centenarians
experience a marked delay in age-related diseases [14], and the
similarity of centenarians’ lifestyles to the general population [15],
all argue that genetic factors play a much stronger role in living
25–35 years beyond the mid-eighties [10,16,17]. Impressively,
siblings of centenarians born in 1900 have a relative risk of living
nearly 100 years that is 8 (females) to 17 times (males) greater than
that for the average of their birth cohort [10]. The rarity of the
trait —only 1 centenarian amongst approximately 5,000 people in
the US and only 1 supercentenarian (age 110+ years) amongst
seven million people [18]— places exceptional longevity in a very
different category from both average life expectancy and common
complex traits associated with aging.
Based upon the hypothesis that exceptionally old individuals are
carriers of multiple genetic variants that influence human lifespan,
we conducted a genome-wide association study (GWAS) of
centenarians. We began with a traditional one SNP at a time
analysis to identify SNPs that are individually associated with
exceptional longevity. We then used a novel approach to build a
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taking into account the simultaneous influence of many genetic
variants, can accurately discriminate between subjects with
average versus exceptional longevity. Next, we used this family
of models to construct subject-specific genetic risk profiles that, by
cluster analysis, can be used to discover sub-phenotypes of
exceptional longevity that are characterized by different genetic
signatures. Figure 1 summarizes the steps of the analyses.
Results
Primary and secondary sets
Our primary set (discovery set) consisted of 801 unrelated
subjects enrolled in the New England Centenarian Study (NECS)
and 914 genetically matched controls. NECS subjects were
Caucasians who were born between 1890 and 1910 with an age
range of 95 to 119 years (median age 104 years). Approximately
one-third of the NECS sample included centenarians with a first-
degree relative also achieving exceptional longevity, thus enhanc-
ing the sample’s power [19]. Controls included 241 genetically
matched NECS referent subjects who were spouses of centenarian
offspring or children of parents who died at an age #73 years, and
673 genetically matched subjects selected from the Illumina
control database. For genetic matching we used a previously
described algorithm [20] that groups subjects by ethnicities based
on cluster analysis of the most informative principal components of
genome-wide genotype data (Figure S1). Note that, based on the
U.S. Social Security Administration’s 1920 birth cohort life table,
the average life expectancy in the cohort is 82 years, with standard
deviation of 7.9 years, so that the mean age of the cases in our
study and the average life expectancy in the cohort differ by 2.69
times the standard deviation. Furthermore, the mean age of NECS
controls was 75 years, with standard deviation 7 years. Therefore,
the difference between mean age of centenarians in the discovery
set and NECS controls was more than 4 times the standard
deviation, thus boosting the power of the study. For replication we
used two additional sets. The replication set 1 (‘‘ELIX’’) consisted
of 253 North American Caucasian subjects enrolled by Elixir
Pharmaceuticals between 2001 and 2003. These individuals were
born between 1890 and 1910 (age range of 89–114 years, median
age 100) and were recruited and phenotyped using a protocol
similar to the NECS. Referent subjects (n=341) were identified
from the remaining Illumina controls and genetically matched to
the 253 cases using the same matching algorithm used in the
discovery set. The replication set 2 was composed of 60
centenarians that included 39 subjects of European ancestry
enrolled in the NECS between June 2009 and September 2010
(age range 100–114, mean age 108) plus 21 centenarians (age
range 101–115, mean age 107) not included in the discovery set
during the genetic matching, and all available Caucasians samples
from the Illumina control database not used in the above
comparisons. Centenarians and controls in replication set 2 were
not genetically matched to test the generalizability of the results.
Figure 2 displays the age distributions of centenarians in the
discovery and replication sets 1 and 2. We also used an additional
set of 867 neurologically normal subjects used as controls for a
Parkinson’s disease GWAS [21], to test the robustness of single
SNP associations. We analyzed 243,980 SNPs that passed a
stringent quality control protocol described in the methods.
Single SNP Analysis
First we conducted a traditional single SNP analysis in which we
ranked SNPs in the discovery set by the strength of association. We
employed both Bayesian and traditional frequentist analyses of 4
different genetic models (general/genotypic, allelic/additive,
recessive and dominant associations) to maximize power [22,23].
With the Bayesian analysis, we scored each SNP association by the
Bayes Factor (BF), which is the posterior odds for the association
Figure 1. Schematic showing the methodology used to discover genetic signatures of exceptional longevity (EL). The analysis
included genetic matching to remove confounding by population stratification between cases and controls of the discovery and replication set 1,
discovery and replication of single SNP associations, multivariate genetic risk modeling and generation of predictive genetic profiles, and cluster
analysis of genetic risk profiles to discover genetic signatures of EL.
doi:10.1371/journal.pone.0029848.g001
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hypothesis of an association have the same prior probability [24],
and then we used the maximum BF (MBF) as a measure of
statistical significance. Figure S2 shows the error rate of decision
rules based on several thresholds for MBF. The matching strategy
appeared to remove confounding by stratification because we did
not observe any inflation of associations and the genomic control
factor in allelic association was 0.99 (Figure S3). We also
conducted additional analyses described below to investigate
whether residual confounding by population stratification could
bias the results and found no evidence of bias.
The Manhattan plot (Figure 3) displays the log10(MBF) for
each tested SNP. This analysis identified a single SNP in APOE/
TOMM40 as irrefutably genome-wide significant (P,10e-8,
Table 1). The association was replicated in the ELIX set, and
was maintained when we used 867 referent subjects included in a
GWAS of Parkinson’s disease as alternative controls (Table 1).
The apolipoprotein E (APOE) is associated with human lifespan
[25,26,27]. SNP rs2075650 occurs in an intron of TOMM40 but it
is a strong proxy of the SNPs that define the APOE alleles [28].
This SNP has been associated with Alzheimer’s disease (AD)
[29,30] and lipid levels [31,32].
Genetic Risk Modeling
In the single SNP analysis, we observed a substantial
enrichment for significant associations which do not meet the
stringent threshold for genome wide significance. For example,
112 SNPs were associated with exceptional longevity with
log10(MBF).2 against an estimated error rate of 4 in 100,000
independent tests and hence 8–10 false positive associations
expected by chance in ,250,000 tested SNPs if there were no
significant associations and all SNPs were independent (Figure
S2). The clusters of associations in chromosomes 8, 9 and 21 in
Figure 3 point to interesting regions, although they fail to reach
genome wide significance. Several authors have argued that SNPs
that do not reach genome wide significance may be biologically
important by virtue of their joint effect [33,34,35,36], and have
successfully built risk models that can predict genetic susceptibility
to several complex traits that are highly heritable [37,38,39,40,41].
We similarly explored the hypothesis that different sets of SNPs
that are associated with exceptional longevity, although with
moderate effects, may jointly characterize the genetic predisposi-
tion to exceptional longevity [42,43] and therefore provide a
model for in silico analysis that can suggest targets and genetic
paths to exceptional longevity.
Selection of Predictive SNPs. To proceed with this analysis,
we had to make several decisions about the class of models to work
with, how to determine the number of SNPs to be included in the
model, and the overall search strategy. We chose to compute the
genetic risk associated with a set of SNPs using a simple but
effective Bayesian classification model, also known as the naı ¨ve
Bayes classifier (Figure 4A) [44]. This approach –also used in [39]
to accurately predict the susceptibility to carotid atherosclerosis –
classifies a subject as predisposed to exceptional longevity if the
posterior probability of exceptional longevity, given genotypes of a
set of SNPs, exceeds the posterior probability of average longevity
(Figure 4A). The advantage of this method is that there is
virtually no upper limit to the number of SNPs that can be used for
classification, and it can be used for risk prediction even if the data
used for the analysis are from a case control study. We designed a
forward search procedure to discover a sufficient number of
predictive SNPs (Figure 4A). The procedure builds a series of
Figure 2. Distribution of age of last contact or age at death of centenarians included in the study. NECS: centenarians of the discovery
set, ELIX: nonagenarians and centenarians from the ELIX replication set, NECS 2: additional NECS replication set of 60 centenarians. The y-axis reports
the density, and the x-axis reports the age, in group of 2 years. The frequency of subjects with ages between x and x+2 is 2*density*(sample size).
doi:10.1371/journal.pone.0029848.g002
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the discovery set and incrementally adding one SNP at a time from
a pruned set of SNPs that are sorted in order of log10(MBF). Each
model is used for prediction, and the accuracy of each model to
predict exceptional longevity and average longevity is evaluated by
sensitivity and specificity (Figure 4B). The trend of sensitivity and
specificity in Figure 4B shows that including more SNPs increases
both sensitivity and specificity but the gain of accuracy becomes
less and less as SNPs with decreasing statistical significance (lower
MBF) are added. Particularly, the sensitivity plateaus between
275–285 SNPs so that including more SNPs does not appear to
improve the sensitivity further (Figure 4B). Because the model
with 281 gives the closest sensitivity and specificity, we stopped the
search for predictive SNPs at 281. We also used a resampling
approach (Figure S4A) to validate this choice, and examined the
effect of changing the SNP order in our heuristic search (Figure
S4C and D), and possible lab-genotyping bias (Figure S4B).
Table S1 provides complete details of all of the 281 SNPs, and
the probabilities that are used to compute the prediction using the
formula in Figure 4A. Reliability of the Illumina genotyping was
double-checked by re-genotyping the top 28 SNPs of the model
using TaqMan genotyping in an independent lab, and the 99.7%
concordance suggests that the data are reliable (Figure S5).
Intensity plots of the 281 SNPs are available from www.bumc.bu.
edu/centenarian. 137 SNPs of the 281 SNPs occur in 130 genes,
some of which have been previously associated with aging such as
LMNA (rs915179), WRN (rs1800392), and SOD2 (rs2758331) and
several of them are in close proximity of coding SNPs [45]. The
LMNA gene, which encodes the nuclear envelope proteins lamin A
and lamin C, has been associated with the progeroid (premature
aging-like) syndrome, Hutchinson-Gilford syndrome [46]. The
WRN gene is a DNA helicase and exonuclease that plays a
deterministic role in DNA repair and another progeroid
syndrome, Werner’s Syndrome [47]. The WRN gene has been
associated with longevity in the Framingham Heart Study (FHS)
sample [48]. It is remarkable that the two genes responsible for the
best known progeroid syndromes appear in the genetic risk model,
and this may reflect the power of the discovery sample which
includes such extreme old ages. Another gene, also noted to be
associated with longevity in the FHS sample as well as the
Jerusalem Study, is SOD2, or superoxide dismutase 2 [49]. SOD2 is
a key free radical scavenger and free radical damage likely plays an
Figure 3. The Manhattan plot displays the maximum log10(Bayes Factor) (y-axis) for each of the analyzed SNPs in the discovery set.
The Manhattan plot displays the maximum log10(Bayes Factor) (y-axis) for each of the analyzed SNPs in the discovery set. The SNPs
are ordered by chromosome (alternate color bands) and, within chromosome, by physical position (x-axis). We tested the association of each SNP
with exceptional longevity using general, allelic, dominant and recessive models and the y-axis reports the maximum log10(Bayes factor) observed
for each SNP. The SNP rs2075650 in APOE/TOMM40 reached irrefutable genome wide significance (log10(MBF)=7.9 and p-value,e-10). Figure S3
shows the Manhattan plot and QQ plot for the additive model using logistic regression.
doi:10.1371/journal.pone.0029848.g003
Table 1. Replication of the association of rs207650 in TOMM40/APOE.
SNP Gene Chrom Alleles Discovery Set (801, 914)
LOG10(BF) p-value OR p(A)
Discovery Set (801, 914) rs2075650 TOMM40/APOE chr19:50087459 AG/GG v AA 6.31 1.03E-08 0.49 0.15/0.26
Replication Set (Elix 253, 341) 2.04 0.000468 0.47 0.15/0.27
Combined (1054, 1255) 9.30 1.01E-11 0.48 0.15/0.26
Coriell (801, 867) 3.73 3.86E-06 0.55 0.15/0.24
The table shows the replicated associations of the SNP rs207650 in TOMM40/APOE in the replication set 1 and the additional control set from the Parkinson’s Disease
study. Column legends: SNP=official dbSNP identifier. Gene=official gene name for SNPs that are within 20 kb from transcribed regions. Chrom=Chromosome and
physical position of SNP in hg18. Alleles=the two SNP alleles (allele 1 v allele 2) in the genetic model that reached strongest significance in the Bayesian analysis.
LOG10(BF)=the logarithm 10 Bayes Factor for the association relative to the null model of no association. Assuming uniform prior probabilities for the two
hypotheses, the BF represents the posterior odds for association. P-value=p-value for 1 degree of freedom test for the dominant model AG/GG versus AA. OR=odds
ratio for exceptional longevity in subjects who carry allele 1 relative to allele 2. For example, subjects who carry the allele 1 (AG/GG) of SNP rs2075650 have 0.49 times
the odds for exceptional longevity compared to subjects who carry the allele 2 (AG/GG: either the genotype AG or GG). P(A)=prevalence of allele 1 in cases and
controls. For example, 15% of centenarians carry the allele AG/GG of SNP rs2075650 compared to 26% of controls. Row 1 shows the results in the discovery set; row 2 in
the ELIX set, row 3 the combined discovery and ELIX datasets and row 4 is the set in which the 914 matched controls of the discovery set were replaced with the
unmatched Coriel controls.
doi:10.1371/journal.pone.0029848.t001
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diseases [50]. CDKN2A (rs1063192) performs a key step in the p53
pathway that has been posited to play a key role in inducing
cellular senescence [51] and it has been associated with adult onset
diabetes [52]. SORCS1 (rs7907713) and SORCS2 (rs6812745) have
been linked AD [53]. Gastric inhibitory polypeptide (GIP),
commonly referred to as glucose-dependent insulinotropic peptide,
encodes a protein that regulates insulin secretion and activates
AKT [54]. The association of this gene (rs9899404) supports the
potential role of insulin regulation in exceptional longevity [55],
and suggests new target genes for human aging beyond FOXO1,
FOXO3A and IGF-IR [56,57,58]. There is also growing evidence of
GIP playing a protective role in both diabetes and AD and GIP is
being investigated as a therapeutic target [59].
We used Genomatix (http://www.genomatix.de) to annotate
the list of 130 genes included in the genetic risk model and the
analysis showed that the list was enriched for several groups of
genes linked to both common and rare diseases (MeSH). Genes
related to Alzheimer’s disease, dementia and tauopathies were the
most significant: 38 of the 130 genes were linked to AD in the
literature (p-value to test the null hypothesis that this happens by
chance was 6.17 e-7) and they are displayed in Figure 5;4 2
genes were linked to dementia (Figure S6, p-value to test the null
hypothesis that this happens by chance was 1.07 e-6) and 38 to
tauopathies (p-value 8.47e-7). The fact that so many genes are
noted to play a role in dementia is consistent with the
epidemiologic finding that dementia is absent or markedly delayed
amongst centenarians (average age of onset, 93 years) [60]. Genes
related to other age related diseases were also significantly
represented: 24 genes were linked to coronary artery disease
(Figure 5), and several genes were linked to neoplasms.
Genetic Risk Profiles and Ensemble of Risk Models. To
better understand the role of these 281 SNPs in shaping the
genetic susceptibility to exceptional longevity, we generated a
genetic risk profile for each subject by plotting the posterior
probability of exceptional longevity (p(EL|Sk), y axis) against the
number of SNPs in each of the 281 SNP sets Sk (x-axis) and
examined their patterns. Figure 6 shows, for example, the profiles
from 3 centenarians and a control. In each profile, an increasing
posterior probability of exceptional longevity shows strong
enrichment of longevity associated variants, because the
posterior probability of exceptional longevity increases when the
profile includes a new SNP genotype that is more frequent in
centenarians than in controls (see methods).
These examplessupport the hypothesis that exceptional longevity
is determined by varying combinations of longevity associated
variants and some number of SNPs may be optimal for classifying
some subjects but not others. Consistent with this observation, we
choose an ensemble of all 281 genetic risk models to compute the
posterior probability of exceptional longevity. This ensemble of 281
genetic risk models provides 89% specificity and sensitivity in the
discovery set (Figure 7A). We next evaluated the predictive
accuracy of this ensemble of models in the two replication sets, the
ELIX set and a recently enrolled sample of NECS centenarians.
Figure 4. A) Schematic illustration of the genetic risk prediction model. We ordered SNPs by maximum Bayes Factor in the discovery set and
built nested SNP sets starting with the most significant SNP and then adding one SNP at a time from the ordered list. The conditional probabilities of
SNP genotypes in centenarians (p(SNPi|EL)) and controls (p(SNPi|AL)) are used to compute the posterior probability of exceptional longevity (p(EL|Sk))
using Bayes’ theorem and prior probability p(EL)=0.5. The classification rule is the standard Bayesian classification rule that is optimal under a 0–1
loss function. B) Sensitivity and specificity of 400 nested models. The x-axis reports the number of SNPs in each of the nested models, and the
y-axis reports sensitivity (% of centenarians with posterior probability of exceptional longevity.posterior probability of average longevity) and
specificity (% of controls with posterior probability of exceptional longevity,posterior probability of average longevity).
doi:10.1371/journal.pone.0029848.g004
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sample) comprised of 253 nonagenarians and centenarians and
341 genetically matched controls were 60% and 58% (Figure 7B)
and AUC=0.58 (Figure S7). Although the distributions of the
predictive scores are significantly different (p-value from t-test
comparing the predicted probabilities of exceptional longevity in
the two groups was 0.001), the discrimination of the model is less
remarkable. Since the ages of subjects in this replication set are
younger compared to the centenarians in the discovery set (median
age in the ELIX set was 100 years compared to 104 in
centenarians of the discovery set) and because we expect that
the genetic component of exceptional longevity increases with age,
we next examined the distribution of the predictive score and the
trend of sensitivity in subsets of subjects with older ages. The
median probability of exceptional longevity in subsets of increasing
age of survival increases to more than 68% in the 81 subjects with
ages .101 (Figure 7C) and, consistently, the sensitivity of the
model to correctly classify older subjects increases with older ages
and reaches 85% in 20 subjects ages 106 and older (Figure 7D).
For example, when the 253 cases of the replication set were
divided into two age groups to better match the ages of the
substantially older discovery set (204 subjects, age ,103, median
age 100 years, and 49 subjects, age $103, median age 105) the
sensitivity of the model was 71% (Figure 7E).
To further investigate our hypothesis that the genetic contribu-
tion to exceptional longevity increases with older ages we
evaluated the sensitivity of the classification rule in a second
replication set of newly enrolled NECS centenarians (n=39) plus
NECS centenarians not included in the discovery set (n=21), the
sum of which had a median age of 107 years (Figure 7F). The
sensitivity was 78% (71.5% in the group of 21 with median age
106 and 82% in the recently enrolled and older group of 39)
confirming increasing sensitivity with increasing ages. The boxplot
in Figure 7F shows that the specificity in an additional set of 2863
controls of replication set 2 was is 61.2%, and the AUC in this
second replication set was 0.74 (Figure S7). Figure S8 shows
that classification rules based on randomly ordering the top 281
SNPs (mid panels) or selecting 281 SNPs at random have lower
sensitivity and specificity.
Our analysis used genetic matching to remove confounding by
population structure. However, since we matched subjects within
clusters, residual stratification might still confound the association
and possibly affect the classification rule. To test the hypothesis
that there is no confounding by residual stratification, we
conducted two traditional analyses. In one analysis, we adjusted
the associations of the 281 SNPs by the top 4 principal
components, and in the second analysis we did not. We then
checked whether adjusting the analysis by the principal compo-
nents would change the results of the unadjusted analysis. Figure
S9 shows that the distributions of p-values for the two analyses in
different genetic models are essentially identical (correlation
coefficient 0.98 to 0.99). This analysis would indicate that there
is no confounding due to residual stratification. We repeated the
analysis adjusting for the top 10 principal components. The effect
of this more stringent adjustment made 3 of the 281 SNPs
borderline significant. We also checked if there is any residual
Figure 5. Genes in the genetic risk models have been linked to coronary artery disease and Alzheimer’s disease. The two networks
display 38 of the 130 genes in the genetic risk model that are linked to Alzheimer’s disease (top) and 24 of the 130 genes that are linked to coronary
artery disease (bottom) in the literature, either by functional or genetic association studies. The nodes that are linked by an edge represents either
genes that are ‘‘co-cited’’ (dashed lines) or ‘‘associated by expert curation’’ (continuous lines). The arrow head means that the associations are
activation (triangle), inhibition (circle), modulation (diamond), conversion (arrow head). The node shape informs about known roles of the genes (see
inset). The nodes that are singleton were linked to AD/CAD in the literature but not together with other genes. The number of genes linked to each
disease was compared to what is expected by chance using Fisher exact test, and the p-values show that the gene seta are unluckily the result of
chance. (Networks generated with Genomatix).
doi:10.1371/journal.pone.0029848.g005
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our model, and there appears to be none (Figure S10).
Genetic Signatures
Some genetic risk profiles were recurrent and we speculated that
groups of centenarians may have genetic risk profiles that are
associated with different sub-types of exceptional longevity such as
different prevalences or ages of onset of age-related diseases. To
test this hypothesis, we used cluster analysis to group the genetic
risk profiles into prototypical signatures. We then investigated
whether groups of centenarians with particular genetic risk profiles
shared specific age-related sub-phenotypes.
Cluster analysis identified 26 groups of 8 to 94 centenarians
(90% of the discovery set) with similar genetic risk profiles, while
10% of the centenarians had rare profiles that occur in groups of 7
centenarians or less. Figure 8 shows, for example, the 9 largest
clusters while all clusters are shown in Figure S11. The
prototypical genetic risk profiles associated with each cluster are
informative displays of the longevity associated variants, and
represent different genetic signatures of exceptional longevity.
While the ensemble of genetic risk models provides a global
estimate of the probability of exceptional longevity, the pattern
itself provides information about the different sets of longevity
associated variants that drive a subject toward this probability.
The same cluster analysis of predicted profiles in centenarians of
the merged replication sets 1 and 2 identified 15 clusters with 8 or
more subjects, while approximately 35% profiles clustered in
groups of 7 or less. The two most predictive and the one least
predictive clusters from the replication set are also shown in
Figure 8. Figure S12 depicts all 15 clusters with 8 or more
subjects in the merged replication sets.
To examine the specificity of the profiles in characterizing
exceptional longevity, we also generated genetic risk profiles of the
control subjects in the discovery set and used cluster analysis to
group them. Only 5 subjects had profiles that predicted
exceptional longevity with more than 90% posterior probability
(Figure S13). Other clusters with more than 8 subjects show that
the majority of these profiles match either the lack of a predictive
genetic signature as in cluster C26 or the sporadic presence of
longevity associated variants of clusters C24–C25 in Figure S11.
To further extend this analysis, we clustered the genetic profiles of
all 4118 controls that include all controls in the discovery and
replication sets 1 and 2. Cluster analysis identified several
signatures, of which only 17% predict exceptional longevity with
Figure 6. Examples of genetic risk profiles in 4 study subjects (3 centenarians with ages at death 107, 108 and 119 years, and a
control). 281 nested SNP sets were used to compute the posterior probability of exceptional longevity in the 4 subjects (y-axis) and were plotted
against the number of SNPs in each set (x-axis). In the 107 year old, the first 5 SNP sets S1=[rs2075650], S2=[S1, rs1322048], …, S5=[S4, rs6801173]
determine a posterior probability of exceptional longevity ranging between 0.54 and 0.28. This subject carries genotypes AA, AG, AG, CC, AA for the 5
SNPs respectively and, with the exclusion of genotype AA of rs2075650 that is more common in centenarians, the other genotypes are more common
in controls than centenarians and determine a posterior probability of exceptional longevity that is lower than the posterior probability of average
longevity. The sixth SNP set, S6=[S5, rs337656], predicts an almost 30% chance of exceptional longevity. The subject carries the AA genotype for the
SNP rs337656 that is more frequent in centenarians (Table S1), and carrying this genotype increases the posterior probability of exceptional longevity.
The probability predicted by the next SNP sets increases steadily and all models with more than 20 SNPs predict more than a 50% chance of
exceptional longevity. This genetic profile shows that the subject carries some combinations of SNP alleles that are associated with exceptional
longevity, while other alleles are associated with ‘‘average longevity’’. However, the overall genetic risk profile determined by all 281 SNP sets makes a
strong case for exceptional longevity because the majority of models predict more than an 80% chance of exceptional longevity. The genetic risk
profile of the centenarian who died at age 119 years is even more convincing: with the exception of the first SNP, all subsequent SNP sets determine
more than a 70% chance of exceptional longevity, and 272 of the 281 models predict more than an 80% chance for exceptional longevity. This profile
shows that this subject is highly enriched for SNPs alleles that are more common in centenarians (longevity associated variants) and that probably
played a determinant role in the extreme survival. The profile of the third subject, age 108 years, shows that different SNP sets determine different
chances for exceptional longevity, and only the overall trend of genetic risk provides evidence for exceptional longevity. The fourth plot displays the
profile of a control, and shows that this subject carries some longevity associated variants; however, the overall trend of genetic risk points to average
longevity rather than exceptional longevity.
doi:10.1371/journal.pone.0029848.g006
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longevity (Figure S14). The most predictive genetic signatures
that characterize exceptional longevity are rare amongst control
subjects, and only 0.6% of the genetic signatures of control
subjects have a posterior probability of exceptional longevity
.0.95.
Interestingly, the patterns of genetic risk profiles that cluster into
genetic signatures distinctly differ from clusters of genetic risk
profiles generated from SNPs selected at random (Figure S15).
We also investigated if some clusters were enriched for specific
ethnicities, but no clusters showed enrichment for any specific
European ethnicity.
We next investigated whether different genetic signatures
correlate with different life spans (Figure 9). Some genetic
signatures were indeed associated with significantly different life
spans. For example, the most predictive signature (C1) was
comprised of centenarians with significantly longer survival
compared to centenarians with signatures C2 (the second most
predictive) or cluster C26 (the least predictive), and the median
survival in centenarians with signature C1 was 105 years
compared to 104 years in centenarians with signature C2 or
103 years in centenarians with signature C26. We observed a
similar result when we compared the survival of centenarians
with the most predictive signatures in the merged replication sets
( R 1a n dR 2 ) ,a n dw h e nw ec o m p a r e dt h es u r v i v a lo f
centenarians with the most and the least predictive signatures
(R1 and R15) (See Figure 9). However, not all signatures
correlated with different survival, for example centenarians with
signatures C1 and C3 did not demonstrate different survival (See
Figure S16). Preliminary analyses provided in the supplemen-
tary material (in need of replication) suggest that the different
genetic signatures of exceptional longevity associate with varying
prevalences and ages of onset of various age-related diseases
(Figure S17, Table S2).
Figure 7. Discrimination of the classification rule based on the ensemble of 281 genetic risk models. Panel A: Posterior probability of
exceptional longevity (EL) and average longevity (AL) (x axis) in the centenarians (red boxplots) and controls (AL1: Illumina controls, blue boxplots,
AL2: NECS controls, green boxplots) of the discovery set (NECS, top left). Both sensitivity and specificity were 89%. The boxplots in blue and green
show that the distributions of the posterior probability of EL in the two control groups are not statistically different (p-value from t-test comparing
the posterior probability of EL=0.21). Panel B: Posterior probability of EL and AL (x axis) in the centenarians (red boxplots) and controls of the
replication set 1. Sensitivity and specificity were 60% and 58% and the distributions of the predictive score are significantly different (t-test p-
value=0.001). Panel C: Median values of the posterior probability of EL (predictive score) in subsets of centenarians of the replication set 1 with
increasing ages. The barplot shows that the median score increases with older ages. Panel D: Sensitivity of the classification rule in subsets of
centenarians of the replication set 1 with increasing ages. The barplot shows the increasing sensitivity in older groups that reaches 85% in 20
subjects aged 106 and older. Panel E: Distribution of the posterior probability of exceptional longevity in the 253 cases of the
replication set divided into two age groups (,103 years, pale blue, mean age 99 years, and $103 years, red, mean age 106). The
sensitivities in the two groups are 57% and 71.4%. The three distributions are significantly different (p-value=0.04 from t-test comparing Illumina
controls and centenarians aged ,103; p-value=0.004 from t-test comparing the centenarians stratified by age). Panel F: Sensitivity and
specificity in an additional set of 2863 controls from the Illumina database (blue), and an additional set of 60 centenarians that
include 39 centenarians enrolled since June 2009 (mean age 108) and 21 centenarians that were excluded from older analysis
because of genetic matching (mean age 106). The specificity in the additional Illumina controls is 61.2%. The sensitivity in the additional
centenarians was 71.5% in the set of 21, and 82% in the additional 39 for a total of 78% (p-value from t-test comparing the posterior probabilities of
EL in controls and centenarians ,1e-10).
doi:10.1371/journal.pone.0029848.g007
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the longevity associated variants discovered in this study, we had
information about familial longevity. Twenty-five percent (n=5)
had .50% of siblings who survived past the age of 90 and some
had evidence for longevity as shown in some pedigrees in Figure
S18. This could indicate that such families have more private or
rare variants not captured by either the genotyping or the model.
Discussion
Though living to very old age runs strongly in families, it is also
a very complex phenomenon with many different patterns of
survival that include disease-free survival but also survival with
various age-related diseases. Given this complexity, it is extremely
unlikely that a single or few genes confer this survival advantage,
but rather it is likely that many genes are involved. To capture this
genetic complexity we developed an approach that uses genetic
risk modeling for in-silico genetics. Our approach includes 3 steps:
1) a single SNP analysis to identify and rank SNPs that are
significantly associated with exceptional longevity, 2) genetic risk
modeling based on nested Bayesian classifiers that produce genetic
risk profiles and 3) cluster analysis of the profiles to discover
genetic signatures and correlate these to different survival patterns
or subphenotypes of exceptional longevity.
Limitations
Although we elected to work with naı ¨ve Bayesian classifiers, many
alternativeapproachestogeneticriskmodelingexist andourmethod
could be extended and/or improved to include for example different
parametric models, or different types of cluster analyses to discover
genetic signatures. We conducted extensive simulation studies to
compareourapproachtologisticregressionthatusethegeneticdata,
ora summaryof thegeneticdata inageneticriskscore.Ouranalyses
show that when all SNPs have an additive effect, using a Bayesian
classifier or a logistic regression model with a weighted genetic risk
score perform equivalently. However, when the genetic effects
include different models of inheritance, such as a combination of
dominant/recessive/generalassociations,thenaBayesianclassifieris
more robust than logistic regression with a weighed genetic risk
score. In eithercase, the approachwechoseguaranteesrobustnessas
indicated in simulation studies (Clustering by genetics ancestry using
genome-wide single nucleotide polymorphisms and incorporating
geneticancestryintogeneticpredictionmodels,Doctoraldissertation
by Nadia Solovieff, May 2011, available upon request). Further-
more, many other ‘‘machine-learning type’’ approaches exist that
can be used to generate genetic risk models, and years of
comparative evaluations in the machine learning community have
shown that there is no clear winner, but different problems require
different solutions [61]. In our search for genetic predictors of
exceptional longevity, Bayesian classifiers appear to perform
reasonably well and can be extended to more general directed
graphical models to include interactions between SNPs and between
genes and environmental factors [62]. Our approach for selecting
predictive features appears to work well in this application. However
othersearchproceduresforfeatureselectionneedtobeexploredand
may produce even better predictive accuracy.
Figure 8. Example of 9 clusters of genetic risk profiles in centenarians of the discovery set and 3 similar clusters in replication sets 1
and 2. In each plot, the x-axis reports the number of SNPs in each genetic risk model (1,…,281), and the y-axis reports the posterior probability of
exceptional longevity predicted by each model. The boxplots (one for each SNP set on the x axis) display the genetic risk profiles of the centenarians
grouped in the same cluster. Numbers N in parentheses are the cluster sizes, and the average posterior probability of exceptional longevity. Color
coding represents the strength of the genetic risk to predict EL (Blue: P(EL|g281).0.95; Red: 0.5,P(EL|g281),0.95; Orange: 0.20,P(EL|g281),0.5;
Green: P(EL|g281),0.2). The full set of 26 clusters is in Figure S11 and includes more than 90% of centenarians in the discovery set.
doi:10.1371/journal.pone.0029848.g008
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For example, our choice of the number of SNPs to be used in the
genetic risk modeling is based on a heuristic rule. The choice of the
optimal number of features to be used in a classifier is a well-
known problem, with no simple solution [44] and to limit the effect
of a sub-optimal selection we used an ensemble of classifiers to gain
robustness. This approach is known to produce better classifiers
than one single model [63]. Our heuristic search orders SNPs by
maximum Bayes factor. Our secondary analyses show that
random reordering of the 281 SNPs decreases the specificity
slightly and selecting SNPs at random from the most significant
1700 SNPs gives models that are less predictive in independent sets
(Figure S4 and S8). If other investigators apply this approach to
other domains, they may want to conduct similar secondary
analyses to evaluate whether the same heuristics lead to better
models.
A major challenge we faced with our genome-wide association
study was the choice of appropriate controls. Because of the
limited number of controls in the NECS, we had to resort to
healthy controls from other genome-wide association studies (the
Illumina control data set and the NECS controls where genotype
data were generated in different labs with different SNP arrays) as
other investigators have done [64]. Our stringent quality control
approach and the genetic matching minimized the number of false
positive associations, likely at the expense of missing some true
positive associations. We decided to use genetic matching to
reduce the effect of population stratification because our initial
genome-wide association study that included all control subjects
from the Illumina repository had a genomic control factor .1.3
suggesting substantial population stratification between cases and
controls. Simulation studies that we published in [65] showed that
matching is a good way to remove the effect of stratification
without losing too much power. In addition, a traditional model
that includes principal components from genome-wide principal
component analysis would not be useful for prediction because the
values of the principal components for new subjects would be
missing. Our analysis does not show any systematic difference
between results in the controls genotyped in our lab compared to
healthy controls genotyped elsewhere (Figures 5 and 8). Also,
additional analyses using traditional principal-components ap-
proaches to control for population stratification suggest that no
residual stratification is likely to confound the associations
(Figures S9 and S10). However, only replication of these results
in independent data from comparably old subjects by independent
investigators will definitively validate the results and this approach.
In our study we included only Caucasian subjects and the extent
to which this analysis applies to other racial groups is an open
question.
Novel insights about the genetics of exceptional
longevity
The large number of SNPs in our genetic risk model and the
variety of genetic signatures confirm that exceptional longevity is
influenced by the combined effects of a large number of SNPs.
The genetic risk model implicates 130 genes, most of them known
to play a role in various disease mechanisms (Figure 5), and our
findings suggest that different variants of these genes may have a
protective role. The most intriguing examples are LMNA and
WRN: while specific variants of these two genes determine
progeria and accelerated aging, alternative variants may increase
life span. About 50% of the SNPs in the genetic risk model are in
intragenic regions and this also suggests that regulatory mecha-
nisms play an important role in exceptional longevity. We also
found that the sensitivity of the prediction in independent sets
Figure 9. Correlation of genetic signatures with lifespan. Panel A: Some genetic signatures are associated with significantly different life-
span. For example the most predictive signature (C1) comprises centenarians with significant longer survival compared to centenarians with
signatures C2 or C26. (p-value 0.01 and 0.02) More examples are in Figure S15. Panel B: The two most predictive genetic signatures and the least
predictive signature in the centenarians of the merged replications sets show consistent results. The comparison between survival of centenarians
with the most predictive signature R1 and the least predictive signature R15 reaches statistical significance, (p-value=0.003) while the comparison
between survival distributions of centenarians with signatures R1 and R2 does not reach statistical significance (p-value 0.10).
doi:10.1371/journal.pone.0029848.g009
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genetic contribution to lifespan increases with increasing ages of
the centenarians.
Our analysis provides further insight about the role of APOE in
survival to extreme ages. Although the SNP rs2075650 in
TOMM40/APOE is the most significantly association with excep-
tional longevity, the value of this SNP to identify who can live to 100
and older appears to be limited. The traces of sensitivity and
specificity of the nested genetic models in Figure 4B show that the
model with only this SNP has 85% sensitivity to predict exceptional
longevitybutonly26%specificity in the discoveryset.Weconducted
anROC analysis to show the poorpredictivevalue ofthisSNP alone
(Figure S19, AUC=0.62). Also, sensitivity and specificity of the
model with only this SNP are 85%/26% in the ELIXIR set, and
82%/23% in the second replication set. The traces of sensitivity/
specificity of the models with increasing number of SNPs show that,
the predictive accuracy increases only when a substantial number of
variants are added to the model that includes rs2075650
(Figure 4B). We also examined the changes in sensitivity/specificity
when we removed this SNP from the list of 281, and dropping
rs2075650 resulted in a loss of approximately 1% accuracy (88%
sensitivity/specificity in the discovery set (AUC=0.95); 55%
sensitivity and 58% specificity in the ELIX set (AUC=0.56); and
75% sensitivity and 60% specificity in the additional 60 centenarians
and 2863 Illumina controls (AUC=0.73)) These results are
summarized in Figure S7. This SNP is only in weak linkage
disequilibrium with the two SNPs that define the 3 alleles of APOE
but its association with longevity was shown to be dependent on the
APOE alleles in [66]. The reason for the low predictive value of
rs2075650 alone is that the GG genotype of this SNP is rare in the
population (genotype frequency 3%) but virtually absent in
centenarians (genotype frequency 0.1%), therefore if someone is a
carrier of the GG allele it is unlikely that he will become a
centenarian, while predicting the outcome in carriers of the AA or
AG genotypes is more difficult without additional genetic data.
The NECS previously showed that centenarians fall into
different groups in terms of age of onset of age-related diseases:
survivors (onset of aging disease #80 years), delayers (onset of
aging disease between 80 and 100 years) and escapers (age of onset
$100 years) [67]. This current analysis now shows that some of
the centenarians carry genetic signatures that correlate with
different ages of survival and suggests that the complexity of aging
and the different patterns of survival to the age of 100 and older
may be the result of different genetic profiles. Unlike the typical
approach of finding individuals with a specific phenotype in
common and then performing a genetic association study to
discover genetic associations with the trait, our approach tries to
dissect a complex phenotype into sub-phenotypes based on the
genetic data. Our analysis is preliminary, based on small a sample,
and needs to be replicated but we hope that this new approach
may prove useful in dissecting other complex genetic traits [68].
While large numbers of longevity associated variants appear to
be necessary for extreme survival, we did not observe a substantial
difference in the numbers of a large sample of known disease-
associated variants carried by centenarians and controls
(Figure 10, Table S3). The Leiden Longevity and Leiden 85+
Studies recently produced similar findings for alleles associated
with specific age-related diseases amongst 85+ year olds and
nonagenarians [69]. Furthermore, only 13 SNPs previously
associated with common diseases in genome wide association
studies reach statistical significance in the discovery set, and the
risk alleles are significantly less frequent in centenarians than in
controls (Table S4) [70,71,72,73,74,75].
These preliminary data suggest that exceptional longevity may
be the result of an enrichment of longevity associated variants that
counter the effect of disease-risk alleles and contribute to the
compression of morbidity and/or disability towards the end of
very long lives [43].
In our analysis we also found that specific signatures correlated
with the prevalence and age of onset of some age-related diseases
Figure 10. Distribution of risk alleles of 1214 SNPs in 1054 centenarians (red) and 4118 controls (blue). Risk alleles were derived from
the GWAS catalogue at the NHGRI (downloaded in April 2011) and the Human Genome Mutation Database. The boxplots displays the rate of risk
alleles carried by centenarians (red) and controls (blue). The disease described are: lupus, cholesterol level (Chol), macular degeneration (MD),
Parkinson’s Disease (PD), Chron’s disease (chr), diabetes (diab), cardiovascular disease (CVD), cance (canc)r, Alzheimer’s (AD), GWAS.pt is the group of
alleles related to personality disorders that were found in GWAS, gwas.qt is the group of alleles related to QTL from GWASs and include cholesterol,
BMI, obesity etc, and GWAS.cc is the group of risk alleles found from case/control GWASs so include for example cancer, PD, MD etc, cod is for coding
variants from the HGMD, and all is the full set of 1214 variants. Table S3 reports the actual rates.
doi:10.1371/journal.pone.0029848.g010
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they predispose for exceptional longevity and for specific, different
patterns of aging. The genetic signatures were built by using an
ensemble of genetic risk models. The high sensitivity of these
predictions in independent samples of centenarians shows that
genetic data can indeed predict exceptional longevity without
knowledge of any other risk factors. The high sensitivity is
consistent with (1) theoretical results that show potentially high
predictability of rare and highly heritable traits even when only
50% of the genetic variants that determine the trait are found [36]
and (2) the accuracy of genetic risk models that have been
developed to predict complex and highly heritable traits
[37,38,39,40,41]. To quantify the amount of genetic variance in
liability to exceptional longevity that is explained by our model, we
used the online calculator http://gump.qimr.edu.au/genroc/ to
translate the predictive accuracy measured by the AUC in
proportion of explained genetic variance on the liability scale
[36]. Based on previous reports and the latest US 2010 Census
(http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf), we
estimated that the prevalence of exceptional longevity (living to
100+) is 1 in every 5,000 people, while the sibling relative risk for
exceptional longevity ranges between 8 and 17 [9,10]. With these
numbers, we estimated that the maximum AUC of a genetic model
of exceptional longevity ranges between 0.95 to 0.98 and our
genetic model that reaches AUC=0.74 in the second replicationset
(Figure S7) explains between 12% to 17% of the genetic variance
on the liability scale. In the ELIXIR replication set, the AUC of our
genetic risk model is 0.58 and this would represent 1–2% of
explained genetic variance. Since the ELIXIR set includes more
nonagenarians than centenarians, and their prevalence in the
population is 0.5% and the sibling relative risk of this trait is
approximately 2.5, we repeated the calculations in this scenario and
the 0.58 AUC translated into approximately 4% of the genetic
variance in the liability scale. These results show that although we
explained a good amount of genetic variability on the liability scale
to live to very old ages, there is still more than 80% missing
heritabilitythat remained tobe explained, andmore comprehensive
geneticstudies have the real potential to decipher the genetic base of
this complex phenotype.
Some centenarians in our study however lack a genetic
signature conducive to exceptional longevity. The strong clustering
of exceptional longevity in some of their families suggests that
these individuals harbor rare or private alleles associated with
exceptional longevity. This in turn would suggest that sequencing
these individuals could be particularly fruitful.
The specificity of our classification rule is 60–61% in the
independent sets and is comparable to other genetic studies of
complex traits [76,77,78]. Although the specificity is better than
random, it would not be useful as a diagnostic test. The decreased
specificity in this study could be explained by the fact that the
control subjects from the Illumina database are primarily made up
of healthy controls used for other genome-wide association studies
and therefore the control data set may be enriched for healthy
aging subjects.
Our finding that about 17% of Illumina controls have signatures
with .70% chance of exceptional longevity (Figure S14) suggests
that a substantial proportion of this group have a genetic
predisposition to exceptional longevity. If this observation is
replicated in more representative samples of the population, it
could in part explain why centenarians are the fastest growing age
group in developed countries [79,80]. At the turn of the last
century, infant mortality was approximately 25%. As public health
measures markedly reduced infant mortality rates in the first
quarter of the 20
th century, a greater and greater proportion of the
population had the opportunity to age into middle and older ages.
If nearly one fifth of the population had an increased genetic
predisposition to survive to 100 years, it is understandable why the
number of centenarians is growing at such a relatively high rate.
Although sensitivity and specificity of our classification rule
may improve with a more comprehensive knowledge of human
genomic variation, its limitations could also suggest that
environmental factors (e.g., lifestyle) contribute in important ways
to the ability of people to survive to very old ages. Replications of
these results in independent cohorts will help to answer these
questions.
Materials and Methods
Ethics statement
NECS and Elixir subjects were enrolled under similar protocols
approved by Boston Medical Center’s Institutional Review Board
and the Western Institutional Review Board, respectively. Written
informed consent was obtained for all NECS and ELIXIR
subjects.
Study populations
The New England Centenarian Study (NECS) began in 1994 as
a population-based study of all centenarians living within 8 towns
in the Boston area [81]. Since ,2000, the NECS expanded
enrollment to include centenarians from throughout the USA
(www.bumc.bu.edu/centenarian). Potential subjects are ascer-
tained via voting records and media alerts. Subjects are sent a
demographic data, life style choices, medical history and
functional status questionnaire, family pedigree form and blood
kit. A dementia scale test is administered over the telephone. The
study is still actively recruiting centenarians, with an average of 50
subjects enrolled per year.
Elixir Pharmaceuticals American Centenarians. In
2001–2003, Elixir Pharmaceuticals (co-founded by Leonard
Guarante and Cynthia Kenyon) conducted a U.S. nation-wide
centenarian recruitment effort. Since 2006, Elixir’s centenarian
research effort has ceased (and DNA and data are stored and have
also been shared with the NECS, where genotyping of all the
samples was performed in 2008). Recruitment and data collection
were modeled after the NECS protocol.
NECS controls. The NECS has recruited approximately 450
referent subjects comprised of spouses of centenarian offspring and
children of parents who died at the mean age of 73 years, with an
age at enrollment ranging between 53 and 90 years.
Illumina controls. We identified 3,613 Caucasian healthy
controls from the Illumina control database (iControlDB, http://
www.illumina.com/downloads/PurposeDocument.pdf).Nopheno-
typic information is available for subjects selected from the Illumina
repository,exceptforgender(,60%females)andage atblooddraw
for some subjects (age range 0—75 years).
The Coriell NINDS control sample in the Parkinson’s disease
(PD) set is described elsewhere [21].
Subjects from these studies were combined to generate a
discovery and replication set using genetic matching (see below)
and an additional replication set in which subjects were not
genetically matched.
Discovery set (NECS). This consisted of 801 cases and 914
controls. Cases are long lived individuals from the NECS who
were born between 1880 and 1910 and reached an age at death
between 95 and 119 (mean 10463, median 104). Controls were
comprised of 673 healthy controls from the Illumina database
(Illumina I), and 241 referent subjects from the NECS. Controls
were selected to match the genetic background of cases.
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individuals enrolled from ELIXIR Pharmaceutical (mean age
10163, median 100), and 341 healthy controls from the Illumina
database (Illumina II). Controls were selected to match the genetic
background of the 253 cases in this set.
Replication 2 (NECS 2). 60 NECS individuals and 2863
healthy controls from the Illumina database (Ilumina III). In this
set, no genetic matching was performed. The 60 centenarians
include 39 subjects of European ancestry enrolled between June
2009 and September 2010 (age range 100–114, mean age 108)
plus 21 centenarians also of European ancestry (age range 101–
115, mean age 107) that were not included in the discovery set
during the genetic matching.
SNP genotyping
We analyzed 1 ug of genomic DNA for NECS and ELIXIR
samples, using the Illumina 370 CNV chip, v.1, the Human610-
Quad v1.0, and the Human 1 M v1.0 (Illumina, San Diego, CA).
We used the Beadstudio software for genotype calling using the
top-strand rule, so that SNPs alleles are coded using lexicograph-
ical order (typically A/G and A/C). The data in the Illumina
repository were generated with different SNP arrays (300 and 550)
and we selected the SNPs that were in common to all platforms.
SNPs with reverse alleles, and monomorphic in some of the arrays
were detected by comparing allele frequencies in controls (300 vs
550, 370 vs 550), and in centenarians (370 vs 1 M, 370 vs 610).
Table 2 summarizes the arrays used.
Quality Control
Rules for sample inclusion. Raw GWAS data were
clustered using standard Illumina cluster definitions in array-
specific batches (all 370 samples together, all 1 M samples
together, all 610 samples together). Specifically, we performed
sample-based QC checks and produced QC statistics to compute
sample call rates (CR). We eliminated all samples with
CR,96.5% and remaining samples were reclustered. After re-
clustering, we included the ‘‘excluded’’ samples using this new
cluster file. If the previously excluded samples had a CR above
93% they were included in the final analysis.
We also used the genome-wide identity by descent analysis in
PLINK [82], to discover unknown relatedness and to estimate
error rate using the number of mismatch of replicated samples
(2%). With this analysis we discovered one subject enrolled in both
the NECS and ELIX studies, whom we removed from the ELIX
set. We also removed samples with inconsistent gender between
heterozygosity of the X chromosome and gender recorded in the
database.
Rules for SNP inclusion. SNPs were included in the final
clean data set if all these conditions were satisfied:
1. CR.98% in each array type (300, 370, 550, 610, 1 M) in both
centenarians and controls of the discovery set, and overall
CR.98% in all samples included in discovery and replication
sets.
2. Cluster separation score .0.25.
3. Excess heterozygosity score between 20.3 and 0.3.
4. Hardy Weinberg equilibrium x
2 statistics in controls ,50.
5. Minor allele frequency difference between any pair of array
type ,0.2
A total of 243,980 SNPs were selected for the analysis.
Assessment of between arrays bias and batch
effects. The 610-Quad is part of the new line of Infinium high
density whole-genome genotyping products, and had undergone
substantial design changes compared to the Human CNV370,
Human 1 M, HumanHap550-Duo and HumanHap300. We used
data from 32 samples that had been genotyped with both the
Human CNV370 and 610-Quad illumina arrays and that
underwent the same QC procedure, to test for systematic bias
between the two arrays. 345,219 SNPs were in common between
the two arrays but only 294,153 SNPs had CR.0.97 (so at least 31
genotypes were called) in both arrays after reclustering. In this set,
915 SNPs had 2 or more different genotypes, and only 28 SNPs had
allele frequencies that differed by more than 0.05. The plot of allele
frequencies (Figure S20) suggests that there is no systematic bias
between arrays but rather sporadic errors that can be identified by
plotting allele frequencies.
We tested the agreement between allele coding in the other
arrays by comparing the allele frequencies. See Figure S21. The
plots rule out general bias between arrays and show that SNPs
with reversed alleles were removed.
The additional sample of 60 centenarians included 39 subjects
that were genotyped in September 2010, using the 610-Quad
array. To be able to test for batch effects, we genotyped the 39
samples in a batch of 48 that included two replicated samples, and
7 samples that had been genotyped with the Human 1 M in the
original analysis. The agreement between genotype calls in the 7
samples genotyped with the 610-Quad and the Human 1 M
ranged between 99.2% and 99.7%.
Table 2. Breakdown of genotyped samples by Illumina SNP array type (columns 3—7), laboratory (column 8), and case/control/
study status (rows).
370 610 1 M 300 550 Lab
Centenarians NECS 583 102 176 0 0 BU
ELIXIR 2 0 9 4 4 000 B U
Controls NECS 2 3 7 4000 B U
Illumina I 0008 9 5 8 4 u n k nown
Illumina II 0006 2 2 7 9 u n k nown
Illumina III 0 0 0 574 2289 unknown
Coriell NINDs 8 6 7 0000 C I D R
The columns of the table denote the Illumina array types. The column ‘‘Lab’’ denotes the laboratory that performed the genotyping: BU=Boston University;
CIDR=Center for Inherited Disease Research. The row Illumina I denotes the control samples included in the discovery set; Illumina II denotes the control samples
included in the first replication set, and Illumina III denotes the residual samples from the Illumina repository; Coriell NINDs denotes the neurologically normal controls.
doi:10.1371/journal.pone.0029848.t002
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Population stratification was assumed to be a serious problem
with the centenarian and control data, because a large proportion
of NECS subjects were immigrants from Europe, and the patterns
of immigration at the end of the 19
th century may lead to an
overrepresentation of some European ethnic groups [83]. In fact,
an initial GWAS analysis in which we randomly selected controls
from the Illumina repository pointed to substantial stratification
(genomic control factor ,1.3). We therefore reduced possible
confounding due to population stratification by selecting controls
to match the genetic backgrounds of NECS subjects.
To identify the population substructure in the centenarians and
controls we ran a principal components analysis with the software
EIGENSOFT [84], using GWAS SNP data for SNPs common to
the NECS and Illumina datasets that had a SNP call rate.0.95
and MAF.0.05. SNPs in strong LD were removed using the
program PLINK with a SNP window of 50 and sliding window of
5 SNPs and we removed 1 SNP from each pair of SNPs with
r
2.0.30 leaving 97,508 SNPs for this analysis. We found that the
top several principal components (PCs) correlated to the genetic
ancestry and formed a similar pattern to other studies of subjects
of European ancestry [84,85]. However, the analysis also showed
that the Illumina controls contain many more ethnic groups than
the NECS (Figure S1), and the inclusion of these control
subjects might therefore inflate false positive associations. We
used the clustering algorithm in [65] to group individuals with
similar ancestry into the same cluster. The algorithm utilizes k-
means clustering to iteratively group individuals into cluster sizes
varying from 2 to 30 and then computes a scoring index at each
cluster size that accounts for the accuracy of the subjects’ cluster
assignments, the stability of k-means clustering from iteration to
iteration and the ability of the algorithm to maximize the distance
between subjects allocated to different clusters. This analysis
identified 20 clusters corresponding to sub-populations with
different genetic structure, and Figure S1 shows the details of
the clusters and their ethnic labels based on the known mother
tongue and ancestry of the cluster members. NECS cases were
present in only 16 of the 20 clusters as shown in Table 3 that
displays the frequency of NECS cases (row 2), NECS controls
(row 3) and Illumina controls (row 4). For example, no
centenarians were allocated to cluster 1 or 15 (empty and full
red dots in Figure S1 that may represent Franks and Celtics-
Alpine ethnicities). To increase the number of controls, we
randomly selected additional Illumina controls from those 16
clusters to maintain the same ratio of cases/controls in each
cluster. For example, we sampled 4 additional Illumina controls
from cluster 2, so that the ratio case/controls in cluster 2 was 21/
24=0.88, and similarly, we sampled 19 additional controls from
cluster 9, so that the ratio case/control in cluster 9 was 31/
35=0.88 etc.
Single SNP Analysis
Bayesian test of association. We employed both Bayesian
and traditional frequentist analyses of four different genetic
models: general in which we analyzed the distribution of three
genotypes; allelic in which we analyzed the distribution of alleles
M versus m; recessive and dominant in which we grouped the
genotypes in two groups, either MM/Mm versus mm (dominant
for TOP strand allele), or MM versus Mm/mm (recessive for TOP
strand allele) respectively. Note that M is the allele in the TOP
strand and m is the allele in the BOTTOM strand based on
Illumina genotype calling rules. We used a traditional x
2 test of
independence in a 263 contingency table to test general
association, and the x
2 test of independence in a 262
contingency table to test additive, dominant and recessive
associations.
With the Bayesian analysis, we scored each SNP association by
the Bayes Factor (BF) that can be interpreted as the posterior odds
for the association when the null hypothesis of no association and
the alternative hypothesis of an association have the same prior
probability [86]. Specifically, let H0 and H1 denote the null
hypothesis of no association between the SNP and the phenotype
and the alternative hypothesis that there is an association between
the SNP and the phenotype, and let p(H0) and p(H1) denote the
prior probabilities of the two hypotheses. Then, by Bayes’
theorem, the posterior odds of the alternative hypothesis is
computed as:
p(H1jdata)
p(H0jdata)
~
p(datajH1)
p(datajH0)
p(H1)
p(H0)
The quantities p(data|H0) and p(data|H1) are the ‘‘marginal
likelihoods’’ of the data, given the two hypotheses H0 and H1, and
are computed as the solutions to the two integrals
p(datajH0)~
ð
p(datajh,H0)p(hjH0)dh and
p(datajH1)~
ð
p(datajh,H1)p(hjH1)dh
The quantities p(datajh,H0) and p(datajh,H1) are the traditional
likelihood functions under the null and alternative hypotheses, and
p(hjH0),p(hjH1) are the prior distributions of the parameters of
the two likelihood functions. These parameters are the conditional
probabilities of the SNPs alleles in cases and controls and, in the
paragraph below, we will provide details of the parameterizations.
The ratio p(data|H1)/p(data|H0) is the BF, so that under the
assumption that p(H0)=p(H1)=0.5, the posterior odds equals the
BF. The BF can be computed in closed form for all 4 models when
appropriate parameterizations are used and missing genotypes are
Table 3. Distribution of NECS cases (row 2), NECS controls (row 3) and Illumina controls (row 4) in clusters of genetic ethnicity
(columns).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Cent 0 21 34 79 27 189 6 0 31 102 22 20 3 94 0 15 94 34 0 25
C o n t r o l 22 08 1 4 3 03 82 1 1 61 91 83 4 1 2432 97 01 2
Illumina 90 310 192 47 278 168 223 104 277 288 200 120 173 132 169 54 266 154 118 250
The table shows the 20 clusters of genetic ethnicity that were discovered using a clustering algorithm described in reference [20]. Note that no centenarians were
allocated to cluster 1 or 15. These clusters are represented by full red dots in Figure S1 and denote Franks and Celtics- Alpine ethnicities.
doi:10.1371/journal.pone.0029848.t003
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below.
We assume that genotypes frequencies in cases and controls
follow independent multinomial distributions with parameters
that follow Dirichlet distributions with uniform prior hyper-
parameters. This is the standard parameterization for conjugate
Bayesian analysis of a contingency table when we condition on one
dimension of the table. See for example the supplement material of
the review article of Balding [86]. In our case, we condition on the
phenotype (case/control status) so that we use the retrospective
likelihood that is appropriate in a case-control design.
Then the marginal likelihood of the data, given a genotype
association, is the formula:
p(DjMassociation)~
C(a1.)
C(a1.zn1.)
Pk
C(a1kzn1k)
C(a1k)
|
C(a0.)
C(a0.zn0.)
Pk
C(a0kzn0k)
C(a0k)
and the marginal likelihood of the data, assuming no association
between SNP and phenotype, is the formula:
p(DjMindependence)~
C(a)
C(azn)
Pk
C(a.kzn.k)
C(a.k)
;
a.k~
X
j ajka~
X
j a.k
where the genotype frequencies nij and hyper-parameters aij of the
Dirichlet distribution are defined in Table 4 and 5. The Bayes
factor is the ratio between the two marginal likelihoods:
Bayes Factor BF~p(DjMassociation)=p(DjMindependence)
The Bayes factors for the other models are calculated using the
same formulas, after the genotype frequencies are converted into
allele frequencies (Table 6), or frequencies for dominant alleles
(Table 7), and recessive alleles (Table 8).
We used ajk=2 in all 4 tests.
For genotype association, we estimated the two ORs for
exceptional longevity (EL) as:
OR(Mm v MM)~
p(MmjEL)p(MMjAL)
p(MmjAL)p(MMjEL)
and
OR(mmvMM)~
p(mmjEL)p(MMjAL)
p(mmjAL)p(MMjEL)
And we estimated the conditional probabilities of genotypes as:
p(MMjEL)~
a11zn11
a1.zn1.
;p(MmjEL)~
a12zn12
a1.zn1.
;
p(mmjEL)~
a13zn13
a1.zn1.
p(MMjAL)~
a01zn01
a0.zn0.
;p(MmjAL)~
a02zn02
a0.zn0.
;
p(mmjAL)~
a03zn03
a0.zn0.
The formulas are similar for the other genetic models. We
estimated the genomic control factor as described in [88].
Interpretation of MBF. We conducted extensive simulations
to compute the expected number of false positive associations of the
decision rule that selects a significant association when the BF of at
least one of the four models is greater than the threshold. For each
allele frequency p(a)=0.05,0.10,0.15,…,0.5, we simulated 100,000
data sets with no associations with 1750 subjects that we randomly
split into 800 cases and 950 controls, to mimic the sample size of the
discovery set. We used thresholds varying between 10 and 1,800
and, in each simulated data set, we computed the BF for the 4
models of association as described above, and determined the SNP
as significantly associated if the BF of at least one of the 4 models
was greater than the threshold. The simulations are summarized in
Figure S2 and show how to interpret different thresholds for the
MBF in terms of expected error rate.
Gender effect. For the significant SNPs in the discovery set,
we testedwhether the associationsaresubstantially modified when a
gender-SNP interaction model was used. We used the retrospective
likelihood and tested whether the distribution of each selected SNP
is independent of the phenotype once we condition on gender.
Accepting the null hypothesis implies that the association between
SNPs and phenotype is explained away by gender and none of the
associations could be explained away by gender.
Table 4. Notation of genotype frequencies.
Genotype Frequencies
MM Mm mm Total
Cases (Y=1) n11 n12 n13 n1.
Controls(Y=0) n01 n02 n03 n0.
Total n.1 n.2 n.3 N
The table defines the mathematical notation for the genotype frequencies used
in the methods.
doi:10.1371/journal.pone.0029848.t004
Table 5. Notation of the hyper-parameters in the Dirichlet
prior distributions.
Prior Hyper-parameters
MM Mm mm Total
Cases (Y=1) a11 a12 a13 a1.
Controls(Y=0) a01 a02 a03 a0.
Total a.1 a.2 a.3 a
The table defines the mathematical notation for the hyper-parameters of the
Dirichlet distribution used in the methods.
doi:10.1371/journal.pone.0029848.t005
Table 6. Notation of allele frequencies in the allelic model.
Allele Frequencies
M M Total
Cases (Y=1) 2n11+n12 n12+2n13 2n1.
Controls(Y=0) 2n01+n02 n02+2n03 2n0.
Total 2n.1+n.2 n.2+2n.3 2N
The table defines the mathematical notation for the allele frequencies used in
the methods.
doi:10.1371/journal.pone.0029848.t006
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62,339 unique SNPs that were associated with a variety of diseases
and traits in several GWASs from the catalogue of published
genome wide association studies at http://www.genome.gov/
26525384 [89], and the Human Gene Mutation Database
(HGMD). We found 1214 of these SNPs in the Illumina array
that we used for the GWAS of EL with acceptable quality. We
calculated the number of disease alleles carried by centenarians
versus all Caucasian controls included in our analysis.
Genetic Risk Modeling
Nested Bayesian Models. We define k nested SNP sets
(k=1,…,K), starting from the most significant SNP
S1~ rs2075650 ½ 
and then we increment the set by adding one SNP at a time in
order of maximum Bayesian factor (MBF). The latter is the
maximum Bayes Factor among the 4 genetic models that we tested
for each SNP in the GWAS. Therefore, the (k+1)th SNP set is
defined as
Skz1 Sk;SNPkz1 ½ 
where SNPk+1 is the SNP with the (k+1)th Bayesian significance.
We choose K=500 that corresponds to testing SNPs with
approximately a posterior probability of an association .0.95,
and removed from this set 100 SNPs that are highly correlated.
To this end, we build a Bayesian network to capture mutual
dependencies between SNPs that represent either strong linkage
disequilibrium or strong SNP-SNP associations and removed those
SNPs that are conditionally independent of the phenotype given
more significant SNPs. We used a threshold on the posterior
probability of association ranging between 10 for multiple
dependencies to 100 for two-way SNPxSNP interaction. The
methodology based on Bayesian networks is described in details in
[62,90].
For each SNP set, Sk, the Bayesian classification rule calculates
the posterior probability of EL as:
p(ELjSk)~
p(EL)Pk
i~1 p(SNPijEL)
p(EL)Pk
i~1 p(SNPijEL)zp(AL)Pk
i~1 p(SNPijAL)
where p(EL) and p(AL)=1-p(EL) are the prior probabilities of
exceptional and average longevity. The conditional probabilities
p(SNPijEL) and p(SNPijAL) represent the distribution of the ith
SNP genotype in cases (EL) and controls (AL). The rule is to
classify a subject as predisposed to exceptional longevity if
p(ELjSk)wp(ALjSk).
We used the prior Pr(EL)=Pr(AL)=0.5 as described in the
caption of Figure 4. This choice of a prior probability 0.5 for both
EL and AL means that the classification becomes independent of
the prior because, by Bayes’ theorem, the rule becomes ‘‘assign
EL’’ if
p(ELjSk)wp(ALjSk)uPi p(SNPijEL)wPi SNPijAL)
and hence when the probability of the data given EL is greater
than the probability of the data given AL.
The quantities
Pk
i~1 p(SNPijEL) and Pk
i~1 p(SNPijAL)
are the joint probabilities of the SNPs in the set Sk that are
estimated from the cases and controls. The rationale of this
formula is that the SNPs are modeled as conditionally independent
given the phenotype so that the probability distribution of a SNP
set, given the phenotype, has the product form
p(SNP1,   ,SNPkjphenotype)~Pi p(SNPijphenotype)
The product form is equivalent to assuming that the SNPs have a
multiplicative effect, as in an additive logistic regression model.
Compared to logistic regression, the Bayesian classification rule
uses the retrospective likelihood to update the prior probabilities of
EL and AL into the posterior probabilities. Also, the product form
in the retrospective likelihood has the advantage that the genetic
effect of each SNP can be estimated independently of the other
SNPs and so there is virtually no upper limit on the number of
SNPs that we can include in the SNP set.
We estimate the conditional probabilities p(SNPijphenotype)
using conjugate Bayesian analysis as described earlier.
Evaluation of sensitivity and specificity. Sensitivity (how
many centenarians are predicted as centenarians) and specificity
(how many controls are predicted as controls) of each SNP set
were estimated as:
Sensitivity=proportion of centenarians in the discovery
set for whom p(EL | Sk)$p(AL | Sk);
Specificity=proportion of controls in the discovery set
for whom p(EL | Sk),p(AL | Sk);
Resampling Method. In the bootstrap-type approach, we
repeatedly split the discovery set into non overlapping 2/3 training
and 1/3 test sets that were respectively used to estimate the nested
genetic risk models and to evaluate their predictive value. We
Table 8. Notation of allele frequencies in the recessive
model.
Allele Frequencies
M M Total
Cases (Y=1) n11 n12+n13 n1.
Controls(Y=0) n01 n02+n03 n0.
Total n.1 n.2+n.3 N
The table defines the mathematical notation for the recessive model for the M
allele in the methods.
doi:10.1371/journal.pone.0029848.t008
Table 7. Notation of allele frequencies in the dominant
model.
Allele Frequencies
MM/Mm Mm Total
Cases (Y=1) n11+n12 n13 n1.
Controls(Y=0) n01+n02 n03 n0.
Total n.1+n.2 n.3 N
The table defines the mathematical notation for the dominant model for the M
allele in the methods.
doi:10.1371/journal.pone.0029848.t007
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summarize the sensitivity and specificity into the average values
(See Figure S4). We evaluated the growth of sensitivity and
specificity in the 1000 resampled sets. The mean number of SNPs
in which the absolute difference between sensitivity and specificity
was ,0.02 and accuracy was .85% was 281.
Effect of the search order. We tested the effect of our
ordering heuristics to see whether different orderings may lead to
better risk prediction models. We conducted two types of tests. In
the first test, we randomly permuted the order of the top 281 SNPs
and repeated the heuristic of building nested genetic risk models
by adding one SNP at a time from the randomized list of SNPs. In
each test, we examined the effect of changing SNP order on the
sensitivity and specificity in the discovery set, and also in the
bootstrap procedure. The results of these analyses are shown in
Figure S4.
Interpretation of genetic risk profiles. We generated
genetic risk profiles for each subject by plotting the posterior
probability of EL (p(EL|Sk), y axis) against the number of SNPs in
each of 281 SNP sets (x-axis). The trend of the profiles informs
about the enrichment of longevity associated variants (LAV)s
because the posterior probability of exceptional longevity in a
subject, given the SNP set Sk+1 is greater than that given the SNP
set Sk if the subjects carries a genotype of the (k+1)th SNP that is
more common in centenarians rather than controls. In fact
p(ELjSkz1)wp(ELjSk) if and only if
p(EL)Pkz1
i~1 p(SNPijEL)
p(EL)Pkz1
i~1 p(SNPijEL)zp(AL)Pkz1
i~1 p(SNPijAL)
w
p(EL)Pk
i~1 p(SNPijEL)
p(EL)Pk
i~1 p(SNPijEL)zp(AL)Pk
i~1 p(SNPijAL)
And the inequality is equivalent to
p(SNPkz1jEL)
w
p(EL)Pkz1
i~1 p(SNPijEL)zp(AL)Pkz1
i~1 p(SNPijAL)
p(EL)Pk
i~1 p(SNPijEL)zp(AL)Pk
i~1 p(SNPijAL)
This can be written as
p(SNPkz1jEL) p(EL)Pk
i~1 p(SNPijEL)zp(AL)Pk
i~1 p(SNPijAL)
  
w
p(SNPkz1jEL)|p(EL)Pk
i~1 p(SNPijEL)zp(SNPkz1jAL)p(AL)Pk
i~1 p(SNPijAL)
which simplifies into
p(SNPkz1jEL)wp(SNPkz1jAL)
Note that this property is independent of the SNPs in the current
SNP set, so changing the order of the nested model may change
the overall pattern of the risk profile but not the interpretation in
terms of enrichment of longevity associated variants.
Ensemble of genetic risk models. The ensemble of genetic
risk models uses 281 nested SNP sets to compute the risk for EL
and AL (average longevity), and the overall risk is estimated as the
average of all genetic risks:
p(ELjS1,   ,S281)~
X281
i~1 p(ELjSi)=281:
Prediction in independent tests. For prediction, we used
the ensemble of 281 genetic risk models trained in the discovery set
and computed the posterior probability of AL and EL in cases and
controls of the two sets. We assumed uniform prior probabilities
(P(AL)=P(EL)=0.5), and classify a subjects as EL if the posterior
probability of EL given the genotype of 281 SNPs was.posterior
probability of AL. We assessed sensitivity and specificity by the
number of centenarians classified as EL and the number of
controls classified as AL.
Genetic Signatures
Clustering of genetic risk profiles. We used the Bayesian
model-based clustering procedure implemented in the program
CAGED [91] to cluster the genetic risk profiles of centenarians
and controls, independently, in the discovery and replication sets.
The method in CAGED is designed to cluster row profiles of a two
dimensional array by preserving the column ordering and it uses a
Bayesian search strategy to identify the number of clusters by
maximizing a Bayesian score [92]. We organized the genetic risk
profiles into a N x 281 array, with rows that represent subjects and
the jth column that represents the genetic risk calculated from the
jth SNP set. We used polynomial models up to order 4 to capture a
variety of patterns [93] and then used hierarchical clustering of the
profiles to check whether similar clusters could be further merged.
The signatures in the merged replication sets were generated by
cluster analysis of the predicted profiles calculated using the 281
genetic risk models trained in the discovery set.
Correlation of genetic signatures with aging sub-
phenotypes. Difference in survival was tested using log-rank
tests implemented in the survival package of R. Only subjects with
events or alive without events were included in the analysis.
Correlation of genetic signatures with race and
ethnicity. We tested the association between the genetic
signatures in centenarians and the genetic structure determined
with the cluster algorithm of the principal components. When we
correlate the 26 clusters of genetic signatures to the clusters of
different population structures, we did not find any association (the
p-value from x
2 was 0.3).
Validation with the TaqMan platform. In order to
validate the genotyping of the SNPs included in the model, 30
SNPs (.10% of the SNPs in the model) were selected to re-
genotype using the TaqMan platform (Applied Biosystems,
Carlsbad, CA). This genotyping was performed at Yale
University. The samples included 688 centenarians and 221
controls from the NECS that were included in the discovery set
and for whom we had available DNA. For each sample, 2.5 ng of
DNA was arrayed into 384-well plates and was dried prior to
TaqMan genotyping. Thermal cycling was performed using either
a BioRad C1000 or S1000 (BioRad, Hercules, CA) and plate reads
were done using the CFX Optical Reaction Module (BioRad,
Hercules, CA). Genotype calls were made using the BioRad CFX
Manager Software for Allelic Discrimination (BioRad, Hercules,
CA). Of the 30 SNPs attempted, 28 SNPs were successfully
genotyped; one zSNP, rs4802234, did not yield data that could be
clustered using the allelic discrimination software for one of the
three 384-well plates, and one SNP, rs12629971, had a lower call
rate (93%). All TaqMan genotyping was performed blind to the
microarray genotypes as the Yale group did not have access to the
microarray genotypes.
There were 34 duplicate samples genotyped using TaqMan
across the 28 SNPs generating a total of 952 duplicate genotypes,
950 of which had both samples called. Of these 950 duplicate
genotypes, 100% of the genotypes were concordant. For the 28
SNPs successfully genotyped, we observed between 1 and 10
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the microarray genotype, yielding concordance rates between
98.88 and 99.89% between genotyping platforms. Our overall
discordance rate across all SNPs was ,1%.
This low rate of discordant genotypes did not affect the results:
23 of the 28 SNPs reached statistical significance in the replicated
data, and although 5 SNPs did not reach statistical significance
possibly because of the small sample of controls, the allele
frequencies from the microarray data and TaqMan data are
virtually indistinguishable (Figure S5), suggesting that a 1%
genotyping error rate should have no impact on this analysis.
Supporting Information
Figure S1 Population structure of centenarians and
controls. Scatter plot of principal components 1 and 2 (PC1
and 2 PC2, top panels), and principal components 3 and 4 (PC3
and PC4, bottom panels) in subjects from the NECS (left) and
Illumina database (right) that were estimated using genome wide
data. We labeled the clusters by ethnicity using the information
about mother tongue and place of birth of NECS subjects and
their parents. Note that some of the European ethnic groups in
controls (NECS and Illumina) are not represented in NECS cases,
for example Italics (ﬂ green), Saxon/Scandinavia (N green),
Celtics/Alpine (& red), and Franks (N N, red).
(TIF)
Figure S2 Error rate in log10 scale of the Bayes rule for
different thresholds of the MBF. The x axes reports the
estimate of the 2log10(error rate) and 95% credible intervals that
were estimated using a Beta distribution in 1,000,000 simulations
per threshold on the MBF (y-axis). The MBF is the maximum
Bayes Factor computed to test the association of each SNP in 4
genetic models (genotypic, allelic, dominant, recessive). The
genotype data were generated with allele frequencies varying
uniformly between 0.05 and 0.5 and assuming HWE. The analysis
suggests that a MBF.1,400 determines an error rate of
approximately 1 to 2 errors per 100,000 tested association
(2log10(2/100,000)=4.7)), and a MBF.100 determines an error
rate of approximately 4 errors per 100,000 tested association
(2log10(4/100,000)=3.4). Note that this analysis includes the
additional costs of searching for 4 genetic models.
(TIF)
Figure S3 Manhattan plot and QQ-plot for the allelic
association tested using a traditional frequentist ap-
proach. The Manhattan plot shows the 2log10(p-value) for the 1
degree of freedom test Chi-square test. The QQ-plot displays the
observed quantiles of the 1 degree of freedom test Chi-square test
versus the expected quantiles.
(TIF)
Figure S4 Effect of sampling variability, and SNP
ordering on the sensitivity and specificity of the model.
Panel A) displays the average sensitivity and specificity of 400
nested models in 1000 resampled sets. 1000 training and test sets
were randomly resampled from the discovery set and each training
set was used to estimate the Bayesian classification rule that was
tested in the test set. The plot displays the average sensitivity and
specificity (y-axis) versus number of SNPs (x-axis). The sensitivity is
the proportion of centenarians with posterior probability of
exceptional longevity.posterior probability of average longevity
and the specificity is the proportion of controls with posterior
probability of exceptional longevity,posterior probability of
average longevity. The mean number of SNPs in which the
absolute difference between sensitivity and specificity was ,0.02
and accuracy was .85% was 281. Panel B) displays the
specificity for the two types of controls in the discovery set (NECS
referent subjects: continuous line; Illumina controls: dashed lines)
and shows that there is no difference between the two control sets.
Panel C) describes the effect of re-ordering the 281 SNPs.
Patterns of sensitivity and specificity using the discovery set (left),
and randomly generated validation sets (right) when the top 281
SNPs were randomly entered into the nested models (continuous
lines: SNPs are ordered by MBF; dashed lines: the same 281 SNPs
are randomly arranged). Panel D) describes the effect of random
selection on sensitivity and specificity of the nested models.
Patterns of sensitivity and specificity using the discovery set (left),
and randomly generated validation sets (right) when 281 SNPs
were randomly chosen from the top 1,700 most significant SNPs.
(continuous lines: SNPs are ordered by MBF; dashed lines: 281
SNPs are randomly selected from the 1700 most significant). The
analysis shows that changing the order affects sensitivity and
specificity of the model. Furthermore, selecting SNPs at random
from the top most significant SNPs gives models that are
consistently less specific and less sensitive.
(TIF)
Figure S5 Correlation between allele frequencies esti-
mated with the TaqMan assay and the arrays. The top
panel shows the agreement between the allele frequencies
estimated with the TaqMan assay in 688 centenarians (x-axis)
and 801 centenarians of the discovery set (y-axis). The bottom
panel shows the agreement between the allele frequencies
estimated with the TaqMan assay in 221 controls of the NECS
included in the discovery set (x-axis) and all 914 controls of the
discovery set (y-axis).The difference between allele frequencies in
the two groups was at most 0.04 (rs6801173). This particular SNP
has substantial variability with ethnicity.
(TIF)
Figure S6 Genes in the genetic risk models have been
linked to dementia. The networks display 42 of the 130 genes in
the genetic risk model that are linked to dementia in the literature,
either by functional or genetic association studies. 38 of the 42 genes
are also linked to Alzheimer’s disease (See Figure 6) and in red are 4
nodes that are specifically linked to dementia but not Alzheimer’s
disease. The nodes that are linked by an edge represent genes that
are either ‘‘co-cited’’ (dashed lines) or ‘‘associated by expert
curation’’ (continuous lines). The arrow head means that the
associations are activation (triangle), inhibition (circle), modulation
(diamond), conversion (arrow head). The node shape informs about
known roles of the genes (see inset). The nodes that are singleton
were linked to dementia in the literature but not together with other
genes. The number of genes linked to dementia was compared to
what is expected by chance using Fisher exact test, and the p-value
1.07e -6 shows that the gene set is unluckily the result of chance.
(Network generated with Genomatix).
(TIF)
Figure S7 Results of the ROC analysis in the discovery
and replication sets. Top panel: We conducted the ROC
analysis using the R package ‘‘validation’’ for the ensemble of 281
nested models. The ensemble of model trained in the discovery set
was then used to predict the outcome in the two replication sets
and the predictions were assessed using ROC analysis. Bottom
panel: ROC analysis of the predictions when the SNP rs2075650in
TOMM40 was removed from the predictive SNPs.
(TIF)
Figure S8 Effect of rearrangement of the top 281 SNPs
and random selection of 281 SNPs from the top 1,700
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(EL) and average longevity (AL) (x axis) in the centenarians (red
boxplots, label EL), nonagenarians-centenarians (light blue, label
NN), Illumina controls (blue boxplots, label AL), in the replication
set 1 (panel 1) and replication set 2 (panel 2). Panels 3 and 4 show
the effect of reordering the nested models, and panels 5 and 6
show the effect of selecting a random set of 281 SNPs from the top
1,700 most significant SNPs. Numbers in parentheses denote the
accuracy in each boxplot ordered from top to bottom. For
example, in panel 1, 58% is the accuracy (=specificity) in controls,
57% is the accuracy (sensitivity) in subjects of the replication set
ages ,103, and 71% is the accuracy (sensitivity) in the
centenarians ages .102. Changing the order of the 281 SNPs
decreases the difference in posterior probability of EL between
centenarians and controls so that the model is less able to
discriminate between centenarians and controls. The effect is even
greater when the SNPs are randomly chosen from the top most
significant.
(TIF)
Figure S9 No evidence of residual stratification on
individual SNP associations. Plot of the 2log10(p-value) of
the 281 SNPs included in the ensemble of genetic risk models. The
x-axis reports the 2log10(p-value) for the unadjusted analysis, and
the y-axis reports the 2log10(p-value) for the analysis adjusted by
the first 4 principal components. The analysis shows that there is
no real change between adjusted and unadjusted analysis
(correlation coefficient=0.98.6, 99.0 and 98.2) and suggests that
population stratification does not appear to confound the
associations. For both analyses, we fit a logistic regression models
using PLINK.
(TIF)
Figure S10 No evidence of residual stratification on
posterior probability of exceptional longevity. Panel A)
Plot of first two principal components (PC1 and PC2) to show the
population structure in centenarians. Panels B and C show the
principal components (PC1, and PC2, x axis) and probability of
exceptional longevity (y-axis). The plot shows that the ranges of
values of probability of exceptional longevity do not change in the
3 groups.
(TIF)
Figure S11 26 genetic signatures of exceptional longev-
ity in centenarians. The profiles fitted in the discovery set were
clustered using CAGED and hierarchical clustering and then
ordered by the average genetic risk. In each plot, the x-axis reports
the number of SNPs in each genetic risk model (1,…,281 SNPs),
and the y-axis reports the posterior probability of exceptional
longevity predicted by each model. Together, the boxplots (one for
each SNP set on the x axis) display the genetic risk profiles of the
centenarians in the same cluster. Numbers in parentheses are the
cluster sizes (N), and the average posterior probability. Color
coding represents the strength of the genetic risk to predict EL
(Blue: P(EL |g281).0.95; Red: 0.5,P(EL |g281),0.95; Orange:
0.20,P(EL|g281),0.5; Green: P(EL|g281),0.2). Only clusters
with 8 or more centenarians are included and describe 90% of all
cases in the discovery set.
(TIF)
Figure S12 Clusters of profiles predicted in the repli-
cation set comprising the ELIXIR subjects and the
additional set of 60 centenarians from the NECS. Only
clusters with 8 or more centenarians are included. Several of the
signatures discovered in the replication set match signatures in the
discovery set: The pattern of R1 matches C1, R2 matches C2, R4
matches C6, R5 matches C11, R8 matches C19, R15 matches
C26. The profiles were generated using the genetic risk models
trained in the discovery set. The profiles were then clustered using
CAGED and hierarchical clustering and then ranked by the
average posterior probability of exceptional longevity per cluster.
(TIF)
Figure S13 Clusters of profiles of the controls in the
discovery set. Genetic signatures in 845 controls subjects of the
discovery set. Numbers in parentheses are the cluster sizes (N), and
the average posterior probability of exceptional longevity per
cluster. Color coding represents the strength of the genetic risk to
predict EL (Blue: P(EL|g281).0.95, Red: 0.5,P(EL|g281),0.95;
Orange: 0.20,P(EL|g281),0.5; Green: P(EL|g281),0.2).
(TIF)
Figure S14 Summary of genetic signatures of excep-
tional longevity in the centenarians of the discovery set
and 4118 controls. We used the nested genetic risk models
trained in the discovery set to compute the genetic profiles of all
controls, and clustered the profiles using the same analytic
strategy. The cluster analysis grouped subjects in 254 clusters of
7 or more, while the remaining subjects had more sporadic
signatures. The pie charts display the distribution of all genetic
signatures in the 801 centenarians of the discovery set (left) and the
4118 controls (right). The slices are color coded as in the previous
figures (Blue: p(EL|g281).0.95; Red: 0.70,P(EL|g281),0.95;
Brown: 0.5,P(EL|g281),0.7; Orange: 0.17,P(EL|g281),0.50;
Green P(EL|g281),0.17). The label P(E) denotes p(EL|g281).
Note the almost lack of ‘‘blue’’ and the dominance of ‘‘green’’ and
‘‘orange’’ signatures in the control set compared to the centenarian
set.
(TIF)
Figure S15 Signatures with random profiles. To compare
the results from cluster analysis of genetic risk profiles and derived
signatures against random results, we randomly selected 300 SNPs
from the list of analyzed SNPs, we generated a set of nested genetic
risk models using the procedure described in the manuscript and
then we tried to cluster the genetic risk profiles. We repeated this
analysis a few times, and consistently showed that sensitivity and
specificity in the replication set were 0.5 (pure chance), and when
we attempted to cluster the genetic risk profiles the analysis
produced many smaller clusters (average size 3 profile per clusters
compared to 15 profiles per cluster in the signatures generated in
the manuscript), many profiles that could not be clustered at all,
and those profiles that could be clustered more effectively were
showing random variability around 0.5.
(TIF)
Figure S16 Age distribution of centenarians in the 26
genetic signatures in the discovery set and in 15
signatures of the merged replication sets. The boxplots
were generated with the R package, and the box displays the ages
at death between the 25
th and 75
th percentile, with median age
depicted as the middle bar. The whiskers extend to the most
extreme data point which is no more than 1.5 times the
interquartile range from the box. The boxplots are ordered by
predictive accuracy of the genetic risk models within clusters.
(Blue: P(EL|g281).0.95,; Red: 0.5,P(EL|g281),0.95; Orange:
0.20,P(EL|g281),0.5; Green: P(EL|g281),0.2). The most
predictive cluster (C1) is associated with the longest median
survival, and other genetic signatures are characterized by
different survivals as well.
(TIF)
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cular disease (CVD), pulmonary disease (CPD), macular
degeneration (MD) and hypertension between centenar-
ians with different genetic signatures. The x-axis reports
age of events, and the y-axis reports the event-free survival
distribution. Only subjects with events were included in the
analysis. The caption below each plot indicates the disease and the
p-value to test significance differences using the log-rank test.
Median ages of onsets are in the insets. Subjects in cluster C1 had
a significant delay in the onset of dementia and stroke, compared
to other clusters. They also delayed onset of cancer compared to
centenarians with signatures C2, C3 and C5, but not differently
from centenarians with signature C6, and delayed cardiovascular
disease compared to centenarians with other signatures but not
differently from centenarians with signature C3. Ages of onset of
other diseases also differ between other clusters.
(TIF)
Figure S18 Pedigrees of 2 centenarians in a cluster
showing no prediction for exceptional longevity (C26).
The two pedigrees show examples of familial longevity although
the genetic risk profiles of the two centenarian probands (red
arrows) show no enrichment of longevity associated variants. This
could indicate that such families have more private or rare variants
not captured by either the genotyping or the model.
(TIF)
Figure S19 Predictive value of the SNP rs2075650 in
TOMM40/APOE in the discovery set. The table reports the
posterior probability of exceptional and average longevity for
different genotypes of rs2075650. The ROC analysis shows that
this SNP alone cannot optimize the trade off between sensitivity
and specificity. The area under the curve is 0.62 compared to 0.95
when 281 SNPs are used in the model (Figure S7, top, left panel).
Note that some threshold on the posterior probability can produce
an accuracy that is worse than random classification.
(TIF)
Figure S20 Plot of allele frequencies in 32 subjects
genotyped with both the Humanhap CNV370 Illumina
array (x axis) and HumanHap 610-Quad Illumina array
(y-axis). Dots in the boundaries of the figure represent
inconsistent SNPs between arrays. Only SNPs that had
CR.97% are included.
(TIF)
Figure S21 Agreement of allele frequencies in different
SNP arrays. Panel A) shows the plot of allele frequencies in 573
centenarians genotyped with array HumanHap370 (x-axis) and
168 centenarians genotyped with the HumanHap 1 M (y-axis).
Panel B) shows the allele frequency in 151 controls typed with
array HumanHap330 (x-axis) and 863 with HumanHap 550 (y-
axis). Panel C shows C) shows the allele frequency in 241 controls
typed with array HumanHap370 (x-axis) and 863 with Human-
Hap 550 (y-axis).
(TIF)
Table S1 List of 281 SNPs included in the genetic risk
model. This is an excel file with 3 worksheets. ‘‘README’’
worksheet describes the column contents; ‘‘281 SNPs’’ worksheet
describes the list of 281 SNPs used in the ensemble genetic risk
models. This includes details about call rate by array type and
phenotype, details of QC, statistical analysis. ‘‘Functional
annotation’’ worksheet includes functional annotation of the 281
SNPs.
(XLS)
Table S2 Disease prevalence in clusters of centenarians
with different genetic signatures. Cardiovascular disease
defined as angina, congestive heart failure, peripheral circulatory
disease or myocardial infarction; pulmonary disease is asthma,
chronic bronchitis or emphysema; hypertension: systolic blood
pressure .140 mm Hg and/or diastolic blood pressure .90 mm
Hg or on medication for HTN.
(DOCX)
Table S3 Rate of disease associated variants carried by
centenarians and controls, and p-value from Student’s T
test. Risk alleles were derived from the GWAS catalogue at the
NHGRI (downloaded in April 2011) and the Human Genome
Mutation Database. The boxplots displays the rate of risk alleles
carried by centenarians (blue) and controls (red). The disease
described are: lupus, cholesterol level (Chol), macular degenera-
tion (MD), Parkinson’s Disease (PD), Chron’s disease (chr),
diabetes (diab), cardiovascular disease (CVD), cance (canc)r,
Alzheimer’s (AD), GWAS.pt is the group of alleles related to
personality disorders that were found in GWAS, gwas.qt is the
group of alleles related to QTL from GWASs and include
cholesterol, BMI, obesity etc, and GWAS.cc is the group of risk
alleles found from case/control GWASs so include for example
cancer, PD, MD etc, cod is for coding variants from the HGMD,
and all is the full set of 1214 variants.
(DOCX)
Table S4 List of disease associated SNPs that showed
significant differences in the discovery sets. Highlighted in
grey are the SNPs with risk alleles that are less common in
centenarians. Some SNPs had unreported risk alleles in the
original publications that are denoted with a question mark.
(DOCX)
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